Impact of Robotic Cochlear Implantation on Hearing Performance in Noise (ROBOT-IC-BRUIT)

February 13, 2025 updated by: Assistance Publique - Hôpitaux de Paris

The purpose of this study is to compare two methods of cochlear implantation : conventional manual insertion versus robot-assisted in order to verify whether robotic insertion provides better performance in the noisy environment.

To do this, we will compare the two methods of insertion of the electrode holder, on 140 patients candidates for cochlear implantation randomized in two groups (70 conventional surgery versus 70 robot-assisted surgery). All patients will be recruited during 17 months, in our Ear, nose and throat (ENT) Department of the Pitié-Salpêtrière hospital group, the first center for adult patients established in France (on average 180 patients/year).

Patient will be followed for 9 months with clinical evaluation, imaging, audiometric, listening effort and quality of life assessments. These evaluations will be carried out preoperatively and postoperatively at 3 months and 6 months post-activation of the cochlear implant.

Study Overview

Detailed Description

In the case of severe (70 to 90dB loss) and profound (>90dB loss) hearing loss, when conventional hearing aids no longer provide sufficient benefit, cochlear implantation remains the only possible solution for hearing rehabilitation. In implanted patients, a clear improvement in communication in silence is observed, but almost all patients have difficulty understanding speech in noisy environments. Cochlear implantation involves inserting an electrode holder into the cochlea during a surgical procedure under general anesthesia. The insertion of the electrode holder must be as minimally traumatic as possible in order to preserve the cochlear structures and avoid post-operative fibrosis that could impact the auditory outcomes.

The conventional method of this surgery is the manual insertion of the electrode holder. In recent years, robotic assistance, the RobOtol®, has been developed with the aim of avoiding the jerks of the surgeon's hand and improving the precision of the insertion. RobOtol® has had its CE marking since 2016 and is used in several hospitals in France and abroad.

Study Type

Interventional

Enrollment (Estimated)

140

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Paris, France, 75013
        • Recruiting
        • Groupe Hospitalier Pitie-Salpetriere
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adult patient ≥ 18 years old
  • Patients with an indication for uni or bilateral, simultaneous or sequential cochlear implantation: severe to profound bilateral deafness with intelligibility ≤70% for Fournier dissyllabic words, in free field, at 60dB with adapted hearing aids.
  • Patient able to understand the information note and give written consent
  • Affiliation to a French social security system

Exclusion Criteria:

  • Patient who does not speak French
  • Etiologies of deafness known to be of bad prognosis (auditory neuropathy, congenital profound deafness, immediate post-meningitis profound deafness, vestibular schwannoma on the side of the ear to be implanted)
  • Impossibility of testing the effect of the cochlear implant alone on hearing results (cochlear implantation in the context of unilateral deafness or fluctuating deafness)
  • Cochlear implantation requiring the use of a perimodiolar electrode holder.
  • Pregnant and breastfeeding women
  • Patients wearing electronic devices, in direct connection with the brain or nervous system
  • Patient included in another interventional study (Jardé 1)
  • Patient under legal protection (guardianship or curatorship) or deprived of liberty

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental arm
Patient having cochlear implantation surgery with RobOtol®.
Patient having cochlear implantation surgery with RobOtol®.
Other: Control arm
Patient having conventional manual cochlear implantation surgery.
Patient having conventional manual cochlear implantation surgery

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Auditory performance in noise with the cochlear implant
Time Frame: At 6 months post-implantation
Evolution of the intelligibility score (Variation of the percentage of words understood) for monosyllabic Lafon words presented at 60 dB SPL with a signal-to-noise ratio of 10 dB (SNR10) between the preoperative score and the score at 6 months post-implantation
At 6 months post-implantation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hearing performance in noise after robotic cochlear implantation compared to conventional manual cochlear implantation for phonemes
Time Frame: At 3 and 6 months post-implantation
Evolution of the intelligibility score (Variation of the percentage of words and phonemes understood) for monosyllabic Lafon words presented at 60 dB SPL with a signal-to-noise ratio of 10 dB (SNR10) between the preoperative score and the score at 3 months and at 6 months post-implantation.
At 3 and 6 months post-implantation
Hearing performance in noise under ecological conditions after robotic cochlear implantation compared to conventional manual cochlear implantation
Time Frame: At 3 and 6 months post-implantation
Evolution of the intelligibility score (Variation of the percentage of words understood) for Fr-Bio words presented at 60 dB SPL with a signal-to-noise ratio of 10 dB (SNR10) between the preoperative score and the score at 3 months and at 6 months post-implantation. The noise will be an ecological noise (restaurant or street noise) using the Immersion® system.
At 3 and 6 months post-implantation
Hearing performance in silence after robotic cochlear implantation compared to conventional manual cochlear implantation for words
Time Frame: At 3 and 6 months post-implantation
Evolution of the intelligibility score (Variation of the percentage of words understood) for monosyllabic Lafon words presented at 60 dB SPL in quiet between the preoperative score and the score at 3 months and at 6 months post-implantation.
At 3 and 6 months post-implantation
Hearing performance in silence after robotic cochlear implantation compared to conventional manual cochlear implantation for phonemes
Time Frame: At 3 and 6 months post-implantation
Evolution of the intelligibility score (Variation of the percentage of phonemes understood) for monosyllabic Lafon words presented at 60 dB SPL in quiet between the preoperative score and the score at 3 months and at 6 months post-implantation.
At 3 and 6 months post-implantation
The subjective benefit on tinnitus after robotic cochlear implantation compared to conventional manual cochlear implantation
Time Frame: At 3 and 6 months post-implantation
Evolution of the Patient's Related Outcomes Measures using questionnaire concerning the tinnitus with the Tinnitus Handicap Inventory (THI)
At 3 and 6 months post-implantation
The subjective benefit on quality of life after robotic cochlear implantation compared to conventional manual cochlear implantation
Time Frame: At 3 and 6 months post-implantation
Evolution of the Patient's Related Outcomes Measures using the questionnaire concerning the quality of life with the Cochlear Implant Quality of Life (CIQOL)
At 3 and 6 months post-implantation
The position of the electrode array in the cochlea during manual and robotic insertions
Time Frame: At day one post -implantation
the position of each electrode will be analyzed blindly on the post-operative CT-scan.
At day one post -implantation
The impact of a translocation on auditory performance in silence and in noise
Time Frame: At 3 and 6 months post-implantation
Auditory scores measured at 3 and 6 months after implantation will be correlated to the presence of a translocation of the electrode array assessed on the post-operative CT scan.
At 3 and 6 months post-implantation
The effort of listening in silence and in noise after manual and robotic insertions assessed with the Speech, Spatial and Qualities of Hearing Scale (SSQ)
Time Frame: At 3 and 6 months post-implantation
The effort of listening will be analyzed with SSQ scale
At 3 and 6 months post-implantation
The effort of listening in silence and in noise after manual and robotic insertions assessed with a visual analog scale
Time Frame: At 3 and 6 months post-implantation
The effort of listening will be analyzed after each audiologic test with a visual analog scale, using which the patient will rate from 0 to 10 the effort made to understand the words presented (Bräcker et al., 2019)
At 3 and 6 months post-implantation
The preservation of residual hearing after cochlear implantation in cases with residual hearing before surgery
Time Frame: At 30 days, 3 months and 6 months post-implantation
Evolution of auditory thresholds measured with tonal audiometry between preoperative and postoperative measurements on the operated ear.
At 30 days, 3 months and 6 months post-implantation
The presence of postoperative vertigo in case of robotic cochlear implantation compared to manual implantation
Time Frame: At 7 days, 3 months and 6 months post-implantation
Evaluation of vertigo with the Dizziness Handicap Inventory (DHI) questionnaire
At 7 days, 3 months and 6 months post-implantation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ghizlene LAHLOU, Dr, Assistance Publique - Hôpitaux de Paris

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 20, 2024

Primary Completion (Estimated)

December 1, 2025

Study Completion (Estimated)

December 1, 2025

Study Registration Dates

First Submitted

December 8, 2023

First Submitted That Met QC Criteria

February 5, 2024

First Posted (Actual)

February 8, 2024

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 13, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

IPD Sharing Time Frame

Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor

IPD Sharing Access Criteria

Researchers who provide a methodologically sound proposal.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Severe to Profound Hearing Loss

Clinical Trials on Surgery with RobOtol®

Subscribe